Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Pharming Group    PHARM   NL0010391025

PHARMING GROUP

(PHARM)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
02/18/2019 02/19/2019 02/20/2019 02/21/2019 02/22/2019 Date
0.852(c) 0.8875(c) 0.87(c) 0.86(c) 0.8455(c) Last
7 607 155 13 566 504 14 834 607 6 963 963 5 554 271 Volume
+1.79% +4.17% -1.97% -1.15% -1.69% Change
More quotes
Financials (EUR)
Sales 2018 136 M
EBIT 2018 43,4 M
Net income 2018 18,3 M
Debt 2018 4,50 M
Yield 2018 -
Sales 2019 169 M
EBIT 2019 56,8 M
Net income 2019 34,4 M
Finance 2019 13,3 M
Yield 2019 -
P/E ratio 2018 27,45
P/E ratio 2019 14,70
EV / Sales2018 3,89x
EV / Sales2019 3,03x
Capitalization 525 M
More Financials
Company
Pharming Group specializes in the development of innovative products for the treatment of genetic disorders, specialty products for surgical indications, and nutritional products. The group's technologies include innovative platforms for the production of protein therapeutics, as well as technology... 
More about the company
Surperformance© ratings of Pharming Group
Trading Rating : Investor Rating :
More Ratings
Latest news on PHARMING GROUP
2018PHARMING : Dutch biotech Pharming plans to challenge big pharma in rare diseases
AQ
2018PHARMING : reports favourable conclusion from first investigator-initiated direc..
PU
2018PHARMING : reports interim financial results for the first nine months of 2018
PU
2018PHARMING : Reports Positive Data From First Investigator-initiated Study of rhC1..
AQ
2018PHARMING : reports positive data from first investigator-initiated study of rhC1..
PU
2018PHARMING : FDA rejects Pharmings Ruconest HAE label expansion
AQ
2018FDA wants extra trial for Pharming's Ruconest as HAE prophylactic
AQ
2018PHARMING : Receives Complete Response Letter from FDA
PU
2018PHARMING GROUP : Corporate Officers and Executives' transactions in the company'..
CO
2018PHARMING : announces further issue of shares as employee options are exercised
PU
More news
Analyst Recommendations on PHARMING GROUP
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02/20GLOBAL MARKETS LIVE : Nissan, Lockheed Martin, UBS, Sainsbury...
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06REGENERON PHARMACEUTICALS : 4Q Profit Rises
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart PHARMING GROUP
Duration : Period :
Pharming Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARMING GROUP
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 1,93 €
Spread / Average Target 128%
EPS Revisions
Managers
NameTitle
Sijmen de Vries Chief Executive Officer
Paul Jai Sekhri Chairman-Supervisory Board
Bruno M. L. Giannetti Chief Operations Officer
Robin Wright Chief Financial Officer
Erica Kerkvliet Senior Director-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PHARMING GROUP11.62%0
IQVIA HOLDINGS INC22.11%28 150
CELLTRION, INC.--.--%23 626
LONZA GROUP13.86%21 316
INCYTE CORPORATION32.33%18 162
SEATTLE GENETICS, INC.26.16%11 437